AtriCure, Inc. (NASDAQ:ATRC) Shares Bought by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 31.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 500,649 shares of the medical device company’s stock after buying an additional 119,929 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in AtriCure were worth $14,038,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Arcadia Investment Management Corp MI acquired a new position in AtriCure in the third quarter valued at about $28,000. Comerica Bank raised its stake in shares of AtriCure by 70.5% in the 1st quarter. Comerica Bank now owns 2,522 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 1,043 shares during the period. nVerses Capital LLC lifted its holdings in shares of AtriCure by 733.3% in the 3rd quarter. nVerses Capital LLC now owns 5,000 shares of the medical device company’s stock worth $140,000 after acquiring an additional 4,400 shares during the last quarter. Quest Partners LLC boosted its position in shares of AtriCure by 38.3% during the 2nd quarter. Quest Partners LLC now owns 5,868 shares of the medical device company’s stock worth $134,000 after purchasing an additional 1,626 shares during the period. Finally, Mount Yale Investment Advisors LLC acquired a new stake in AtriCure in the 1st quarter valued at approximately $224,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Up 0.2 %

ATRC opened at $35.74 on Friday. The stock has a market capitalization of $1.74 billion, a P/E ratio of -43.05 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. AtriCure, Inc. has a one year low of $18.94 and a one year high of $42.99. The business’s 50-day simple moving average is $30.93 and its 200-day simple moving average is $25.87.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. The company had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.20) earnings per share. Analysts anticipate that AtriCure, Inc. will post -0.72 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on ATRC shares. Canaccord Genuity Group upped their price target on AtriCure from $49.00 to $53.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Stifel Nicolaus lowered their target price on AtriCure from $30.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. StockNews.com upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research note on Saturday, September 14th. JPMorgan Chase & Co. increased their price target on shares of AtriCure from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Finally, BTIG Research dropped their price objective on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.11.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.